$56.45
3.02%
Nasdaq, Apr 21, 07:44 pm CET
ISIN
US45337C1027
Symbol
INCY
Sector
Industry

Incyte Stock price

$58.21
-3.80 6.13% 1M
-8.22 12.37% 6M
-10.86 15.72% YTD
+5.49 10.41% 1Y
-22.12 27.54% 3Y
-41.79 41.79% 5Y
-43.45 42.74% 10Y
Nasdaq, Closing price Thu, Apr 17 2025
+0.48 0.83%
ISIN
US45337C1027
Symbol
INCY
Sector
Industry

Key metrics

Market capitalization $11.27b
Enterprise Value $9.17b
P/E (TTM) P/E ratio 214.64
EV/FCF (TTM) EV/FCF 36.81
EV/Sales (TTM) EV/Sales 2.16
P/S ratio (TTM) P/S ratio 2.66
P/B ratio (TTM) P/B ratio 3.27
Revenue growth (TTM) Revenue growth 14.76%
Revenue (TTM) Revenue $4.24b
EBIT (operating result TTM) EBIT $80.14m
Free Cash Flow (TTM) Free Cash Flow $249.07m
Cash position $2.16b
EPS (TTM) EPS $0.27
P/E forward 13.26
P/S forward 2.41
EV/Sales forward 1.96
Short interest 6.58%
Show more

Is Incyte a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,780 stocks worldwide.

Incyte Stock Analysis

Unlock Scores for Free

Analyst Opinions

28 Analysts have issued a Incyte forecast:

9x Buy
32%
18x Hold
64%
1x Sell
4%

Analyst Opinions

28 Analysts have issued a Incyte forecast:

Buy
32%
Hold
64%
Sell
4%

Financial data from Incyte

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
4,241 4,241
15% 15%
100%
- Direct Costs 378 378
20% 20%
9%
3,864 3,864
14% 14%
91%
- Selling and Administrative Expenses 1,087 1,087
7% 7%
26%
- Research and Development Expense 2,607 2,607
60% 60%
61%
169 169
77% 77%
4%
- Depreciation and Amortization 89 89
8% 8%
2%
EBIT (Operating Income) EBIT 80 80
88% 88%
2%
Net Profit 33 33
95% 95%
1%

In millions USD.

Don't miss a Thing! We will send you all news about Incyte directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Incyte Stock News

Neutral
Business Wire
11 days ago
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq: INCY) announced today that it has scheduled its first quarter financial results conference call and webcast for 8:00 a.m. ET on Tuesday, April 29, 2025. The schedule for the press release and conference call/webcast is as follows: Q1 2025 Press Release: April 29, 2025 at 7:00 a.m. ET Q1 2025 Conference Call: April 29, 2025 at 8:00 a.m. ET Domes...
Neutral
Business Wire
14 days ago
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
Negative
Market Watch
21 days ago
Stocks turned higher on Monday afternoon to finish March on a positive note. Still, the S&P 500 ended with a 5.8% decline for March, with 69% of component stocks down for the month.
More Incyte News

Company Profile

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development and commercialization of proprietary therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late stage development, and commercialized products such as JAKAFI (ruxolitinib), and ICLUSIG (ponatinib). The company was founded by Roy A. Whitfield in April 1991 and is headquartered in Wilmington, DE.

Head office United States
CEO Herve Hoppenot
Employees 2,617
Founded 1991
Website www.incyte.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today